PFE and S1GE34 Related Headlines
Go Back- Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
- PADCEV plus Keytruda reduces bladder cancer recurrence risk by 47%
- PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
- Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
- PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
- FDA approves PADCEV plus Keytruda for bladder cancer patients
- U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
- Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance
- PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
- Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025
- PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
- Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance
PFE and S1GE34 Related Press Releases
Go Back- Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
- PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer
- Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
- PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
- Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
- U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer
- Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance
- PADCEV™ Plus KEYTRUDA™, Given Before and After Surgery, Cuts the Risk of Recurrence, Progression or Death by 60% and the Risk of Death by 50% for Certain Patients with Bladder Cancer
- Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025
- PADCEV™ Plus KEYTRUDA™ Significantly Improves Survival for Certain Patients with Bladder Cancer When Given Before and After Surgery
- Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance
